Semaglutide (NN9535)
Synthetic 31-amino-acid GLP-1 receptor agonist with 94% sequence homology to native human GLP-1, modified with an albumin-binding C18 diacid spacer. Marketed by Novo Nordisk as Ozempic (injectable T2D), Rybelsus (oral T2D), and Wegovy (injectable obesity & cardiovascular risk reduction). Approved globally.
60-Second Scientific Briefing
Semaglutide is an FDA-approved synthetic GLP-1 receptor agonist indicated for type 2 diabetes glycemic control (Ozempic, Rybelsus), chronic weight management (Wegovy), and cardiovascular risk reduction in established cardiovascular disease. It functions by mimicking endogenous GLP-1 incretin action.
What is Semaglutide?
Pharmacological Classification & Molecular IdentitySynthetic acylated GLP-1 analogue with 94% amino acid sequence homology to human endogenous GLP-1(7-37).
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingBiological pathway and target receptor binding mechanism.
Receptor Selectivity: Selective agonist at GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, and slowing gastric emptying.
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsFDA Approved for Type 2 Diabetes (Ozempic NDA 209637, Rybelsus NDA 213051) and Chronic Weight Management (Wegovy NDA 215256).
Semaglutide has received regulatory approval for specific medical indications. Commercial distribution and medical usage require appropriate prescription and adherence to approved labeling.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesExtensive global Phase 3 programs: STEP (weight management) demonstrating up to 14.9% mean weight loss at 68 weeks, and SUSTAIN (type 2 diabetes/cardiovascular outcomes).
Clinical Evidence
Extensive global Phase 3 programs: STEP (weight management) demonstrating up to 14.9% mean weight loss at 68 weeks, and SUSTAIN (type 2 diabetes/cardiovascular outcomes).
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesGastrointestinal adverse events (nausea, vomiting, diarrhea, constipation). Boxed warning for thyroid C-cell tumors in rodent studies; contraindicated in patients with Personal or family history of MTC or MEN 2.
Degree of weight regain following drug cessation and long-term surveillance of rare gastrointestinal motile complications (e.g., severe gastroparesis/ileus).
Dose Approval Status
Commercial Dosing Status and Policy DirectivesFDA-approved maintenance doses: 0.5 mg, 1.0 mg, or 2.0 mg weekly for Ozempic; 2.4 mg weekly for Wegovy, initiated via strict monthly dose escalation.
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Synthetic acylated GLP-1 analogue with 94% amino acid sequence homology to human endogenous GLP-1(7-37).
- Targets & Selectivity: Selective agonist at GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, and slowing gastric emptying.
- Extensive global Phase 3 programs: STEP (weight management) demonstrating up to 14.9% mean weight loss at 68 weeks, and SUSTAIN (type 2 diabetes/cardiovascular outcomes).
- Safety considerations: Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation). Boxed warning for thyroid C-cell tumors in rodent studies; contraindicated in patients with Personal or family history of MTC or MEN 2.
? Unknown / Under Ongoing Investigation
- Degree of weight regain following drug cessation and long-term surveillance of rare gastrointestinal motile complications (e.g., severe gastroparesis/ileus).
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysSemaglutide is classified as a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist. Molecular structure: Synthetic acylated GLP-1 analogue with 94% amino acid sequence homology to human endogenous GLP-1(7-37)..
Pharmacological classification and molecular integrity are documented in verified regulatory and scientific literature.
- FDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2021-06-04)
Semaglutide exerts biological activity via Selective agonist at GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon secretion, and slowing gastric emptying..
Receptor binding affinity and selectivity dictate the physiological response observed in laboratory and clinical trials.
- FDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2021-06-04)
Regulatory status: FDA Approved for Type 2 Diabetes (Ozempic NDA 209637, Rybelsus NDA 213051) and Chronic Weight Management (Wegovy NDA 215256).
Prescription use requires a verified medical diagnosis and adherence to approved labeling.
- FDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2021-06-04)
Clinical evaluation status: Extensive global Phase 3 programs: STEP (weight management) demonstrating up to 14.9% mean weight loss at 68 weeks, and SUSTAIN (type 2 diabetes/cardiovascular outcomes).
Clinical trial readouts and systematic analyses establish the boundary between demonstrated findings and experimental hypotheses.
- FDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2021-06-04)
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (New England Journal of Medicine, 2021-03-18)
Reported safety profile: Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation). Boxed warning for thyroid C-cell tumors in rodent studies; contraindicated in patients with Personal or family history of MTC or MEN 2.
Adverse reaction monitoring and contraindications are critical parameters in pharmacological risk-benefit evaluation.
- FDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2021-06-04)
Key scientific uncertainties: Degree of weight regain following drug cessation and long-term surveillance of rare gastrointestinal motile complications (e.g., severe gastroparesis/ileus).
Egypt Peptides enforces strict transparency regarding scientific limitations and gaps in longitudinal clinical data.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (New England Journal of Medicine, 2021-03-18)
FDA-approved maintenance doses: 0.5 mg, 1.0 mg, or 2.0 mg weekly for Ozempic; 2.4 mg weekly for Wegovy, initiated via strict monthly dose escalation.
Under medical governance mandates, clinical study dosages represent strictly controlled experimental parameters and must never be interpreted as individual therapeutic advice.
- FDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2021-06-04)
Storage status: Store refrigerated at 2°C to 8°C (36°F to 46°F). Prior to first use, protect from light. Once in use, pens can be stored at room temperature up to 56 days (Wegovy) or 56 days (Ozempic).
Peptide integrity degrades rapidly when exposed to elevated temperatures, repeated freeze-thaw cycles, or direct UV light exposure.
- FDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2021-06-04)
Athletic status depends on WADA category classification; peptide hormones, growth factor mimetics, and related substances are prohibited under WADA Section S2.
Athletes subject to drug testing face strict liability and multi-year competition bans upon detection of prohibited peptides or their metabolites.
- FDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2021-06-04)
Egypt Peptides provides peer-reviewed scientific reference monographs for research documentation. We strictly prohibit individual medical consultations, reconstitution guides, stacking recipes, or off-label use instructions.
All scientific claims must link to verified authoritative sources (FDA, PubMed, ClinicalTrials.gov) with zero tolerance for ungrounded marketing claims.
- FDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information (U.S. Food and Drug Administration, 2021-06-04)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and peer-reviewed studiesFDA Drugs@FDA Database: WEGOVY / OZEMPIC (Semaglutide) Approval History and Prescribing Information ↗
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
Once-Weekly Semaglutide in Adults with Overweight or Obesity ↗
https://www.nejm.org/doi/10.1056/NEJMoa2032183